Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response
NCT01397903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 545
Last updated 2012-06-25
Summary
The purpose is to assess the response of add-on therapy, based on CGI-I scale, at 4 weeks, in patients with MDD who had an inadequate disease control with antidepressant medication.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Panagiotis Pontikis · Marketing Company Medical and Regulatory Affairs Director, AstraZeneca S.A. Greece
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-09-30
- Primary Completion
- 2012-03-31
- Completion
- 2012-03-31
Countries
- Greece
Study Locations
More Related Trials
-
AZD6765 Severe Major Depressive Disorder (MDD) IV
NCT00781742 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
NCT05952713 ·Status: COMPLETED
-
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 ·Status: COMPLETED ·Phase: PHASE2
-
AZD7268 Safety and Tolerability Study
NCT01020799 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)
NCT00035282 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
NCT00411099 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
NCT04937829 ·Status: COMPLETED ·Phase: PHASE1
-
Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression
NCT02132286 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 ·Status: TERMINATED ·Phase: PHASE3
-
Patient Tolerability Study of GSK163090
NCT00559299 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397 ·Status: RECRUITING ·Phase: PHASE3
-
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030 ·Status: COMPLETED
-
AZD6765 for Treatment Resistant Depression
NCT00491686 ·Status: COMPLETED ·Phase: PHASE2
-
Early Versus Delayed Switch in Medication in Patients With Major Depressive Disorder
NCT00810069 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)
NCT00035009 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy
NCT04463108 ·Status: COMPLETED
-
Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder
NCT06532604 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111565 ·Status: TERMINATED ·Phase: PHASE3
-
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202 ·Status: COMPLETED ·Phase: NA
-
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
NCT05973851 ·Status: RECRUITING ·Phase: PHASE3
-
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression
NCT00320632 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
NCT00035295 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
NCT05061706 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.
NCT00775203 ·Status: COMPLETED ·Phase: PHASE3